Search PubMed⌕ Search

Biomedical subjects

N Wade

Publications and source records attributed to N Wade.

At least 37 records · Page 2Linked to original sources
PubMed1993

Intravenous disodium etidronate therapy in spinal cord injury patients with heterotopic ossification.

The goal of the present study was to use intravenous etidronate in the acute phase of heterotopic ossification (HO) in an attempt to achieve a high initial drug concentration at the site of the active ectopic ossification. The study included 27 consecutive patients with an acute onset of HO after spinal cord injury (SCI). The three-phase bone scan was used to confirm clinical diagnosis of HO. Disodium etidronate (Didronel) 300 mg was administered intravenously daily for 3 to 5 days. In 20 patients there was a rapid (1-2 days) decrease of soft tissue swelling (p < 0.01) with no side effects associated with the intravenous administration. In seven patients there was minimal or no improvement of edema after intravenous etidronate. In these patients deep vein thrombosis was found in the affected limbs. The effect of high dose etidronate on HO was determined in the group of 13 patients with positive clinical and scintigraphic finding of an acute HO, but negative radiographic studies. After intravenous administration of etidronate for 3 days (300 mg/day) the drug was continued orally with 20 mg/kg/day for 6 months. A placebo was not used in this study. In eight patients there was no radiographic evidence of HO after therapy while two patients had minimal ossifications. In three patients therapy was interrupted and all developed HO in 1-2 months.

Administration, Oral↗
PubMed1992

Faces of psychology.

Explore the source record for details and available documents.

History, 17th Century↗
PubMed1991

Guidelines for the care of children and adolescents with HIV infection. Immunologic considerations in pediatric HIV infection.

The pervasive effect of HIV infection on the immune system requires that the clinician be alert to the variety of immunologic abnormalities that can result from this disease. The tests described in this section provide guidelines for testing the HIV-infected child. Additional information on immunologic evaluations in the child with indeterminate HIV infection status can be found in the article on ambulatory care.

Acquired Immunodeficiency Syndrome↗
PubMed1991

Decreased incidence of urinary tract infections in patients with spinal cord injury: effect of methenamine.

This study was designed to determine the effect of methenamine on the frequency of urinary tract infections (UTI) in hospitalized patients after spinal cord injury. The study included 56 patients with neurogenic bladder dysfunction treated with intermittent catheterization. A group of 34 patients was treated with methenamine, 1g twice daily; the other group of 22 patients was the control group receiving no antimicrobial therapy. On a weekly basis urine samples from all patients were obtained for urinalysis and culture. A total of 500 urine samples were analyzed. The patients treated with methenamine had 23.4% positive urine cultures which was significantly lower than 57.5% in the untreated control group (p less than 0.001). Our data suggest that methenamine therapy is an effective prevention of UTI in paralyzed patients with neurogenic bladder dysfunction during the rehabilitation in hospital.

Bacteriuria↗
PubMed1984

Biotechnology and its public.

The author provides a perspective on three key areas of biotechnology: the public debate over hazards, the commercialization of the technology, and ethical issues that are arising in terms of application of genetic therapy to humans. He reviews the history of the recombinant DNA research debate beginning at Asilomar in 1975, when the molecular biologists called for a temporary moratorium on certain experiments, so the NIH might develop guidelines to govern this research. The author then characterizes the lobbying activities of the biologists against proposed regulation at the federal, state and local level. Despite the lobbying, he concludes that Congress did not enact legislation because of the exemplary behavior of the biologists, beginning with their meeting at Asilomar. The author next describes the impact commercialization of this technology will have on academic biologists who traditionally have not been involved in that process (as have chemists and physicists). He also comments on the ethics of biotechnology, concluding that the more powerful biology becomes, the more its uses and some control of those uses will be debated.

Biotechnology↗